contract research organization Archives

ATLANTA, Ga. /ScoopCloud/ -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

With an unwavering commitment to excellence, Divergent CRO provides a wide range of services, including clinical trial management, regulatory affairs, data management, biostatistics, and medical writing. By leveraging our extensive expertise, we are dedicated to helping our clients accelerate the development of innovative biopharmaceuticals and medical devices.

Our team of highly skilled professionals, including experienced clinical researchers, project managers, and regulatory specialists, is dedicated to delivering the highest standards of quality and efficiency throughout each stage of the clinical trial process. We understand the challenges faced by biotech and device companies and are committed to providing flexible and cost-effective solutions to meet their specific needs.

Divergent CRO is equipped with cutting-edge technology and infrastructure to ensure the smooth execution of clinical trials. Our advanced data management systems and secure facilities ensure the confidentiality and integrity of study data, while our robust quality assurance processes guarantee compliance with regulatory requirements.

"We are thrilled to launch our new Contract Research Organization and partner with biotech and device companies to advance the development of life-changing therapies," said Divergent CRO's Owner-Partners. "Our team is dedicated to delivering exceptional results and providing the highest level of service to our clients. With our expertise and commitment to excellence, we are confident that we can make a significant impact on the success of their clinical programs."

Divergent CRO is now accepting inquiries and is available to discuss collaboration opportunities with biotech and device companies seeking to enhance their clinical research capabilities.

For more information, please visit Divergentcro.com or contact our business development team at Customerservice@divergentcro.com or (888) 342-1447.

About Divergent CRO:

Divergent CRO is a leading provider of clinical services to biotech and device companies. With a focus on innovation and quality, we strive to accelerate the development of life-changing therapies through our comprehensive and tailored clinical services. We thrive on leaving our clients and patients satisfied by improving human health and wellness. Our team of experts is dedicated to delivering exceptional results and providing the highest level of service to our clients. At Divergent CRO, we don't just manage clinical trials; we craft personalized solutions, striving to be the difference by transforming challenges into triumphs in the pursuit of groundbreaking healthcare innovation.

Learn more at: https://divergentcro.com/

Social Links:

LinkedIn Page: https://www.linkedin.com/company/divergentcro/

Instagram: https://www.instagram.com/divergent.cro/

TikTok: https://www.tiktok.com/@divergentcro1

YouTube: https://www.youtube.com/@DivergentCRO

Featured Podcasts:

The Jali Podcast - Melyssa Barrett/DivergentCRO - https://melyssabarrett.com/the-jali-podcast/

Episode Thirty-one - AMY HUTTO, PRODUCTIVITY COACH - https://amyhutto.com/podcast/s1ep30

Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

Related link: https://divergentcro.com/

VENTURA, Calif. /ScoopCloud/ -- Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).

After experiencing recurrent C.diff Infection (CDI) following hospitalization for pneumonia, the patient sought the expertise of Dr. Hazan, a gastroenterologist and microbiome expert. Since the patient previously failed several courses of antibiotics for CDI, with relapse confirmed via symptom recurrence and positive stool test, Dr. Hazan presented the option of fecal transplant (FMT). FMT involves the transfer of stool from a healthy individual to deliver healthy microbes to the gut of an ill patient. FMT can be used to treat CDI not responsive to standard therapies.

After a detailed discussion regarding the potential risks and benefits associated with the procedure, the patient underwent a single 300 mL FMT infusion using stool from his 85-year-old wife as a donor. At the time, the patient had scored 20 on his most recent Mini-Mental State Examination (MMSE) administered by a neurologist, indicating mild cognitive impairment. The patient's wife, on the other hand, was intellectually acute, with normal affect and stable mood.

Following the procedure, the patient's CDI symptoms resolved, and repeat stool testing two months later was negative. Additionally, the patient's wife reported improvements in his mental acuity and affect at the follow-up visit two months post-FMT. The MMSE was re-administered by the gastroenterologist and neurologist, and the patient scored 26, indicating normal cognition.

Four months post-FMT, the patient reported continued improvement in memory, with no progression in symptoms. The patient even remembered his daughter's birthday, which he was previously unable to recall. Six months post-FMT, the patient reported a marked improvement in mood, was more interactive, and showed more expressive affect. Readministration of the MMSE revealed that the patient's score had further increased to 29. The maximum MMSE score is 30 points.

Dr. Hazan is a specialist in gastroenterology, internal medicine and hepatology. She is the founder & CEO of ProgenaBiome, a genetic sequencing research laboratory dedicated to understanding the clinical implications of the microbiome.

"To our knowledge, this is the first report of a case of rapid symptom improvement of AD symptoms in a patient following FMT for recurrent CDI," says Dr. Hazan. "Based on the findings of this case and the analysis of the genetic sequencing of the gut flora, we will now submit an investigative new drug (IND) application for 20 additional Alzheimer's patients to undergo fecal transplant. We hope to reproduce this case and develop a stool marker that can help patients prevent Alzheimer's in the future."

While this case is a proof of concept for one patient, Dr. Hazan looks forward to expanding her work. She is currently seeking funding to expand the clinical trial for Alzheimer's improvement via FMT.

Dr Hazan also assembled the BIOME SQUAD, a group of her colleagues and fellow FMT doctors. The Biome Squad will be presenting data on the microbiome and fecal transplant at the Malibu Microbiome Meeting.

There will be a Virtual Prelude Rerun on October 14, 4 p.m. PT/PDT. For details and registration, visit: https://malibumicrobiomemeeting.com/

Read the full Alzheimer's report: https://journals.sagepub.com/doi/10.1177/0300060520925930

Interviews / Investors, Contact: Stephanie Davis, sdavis@progenabiome.com

Support ongoing research: https://microbiomeresearchfoundation.com/

About ProgenaBiome:

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, ProgenaBiome has 42+ ongoing clinical trials related to immunity and disease with six COVID-19 studies validating testing, prophylaxis, and treatment protocols for the novel coronavirus.

For more, visit https://progenabiome.com

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/20-1006s2p-malibu-microbiome-300dpi.jpg

Caption: Malibu Microbiome Meeting poster.

Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).

Related link: https://progenabiome.com/

ScoopCloud

The affordable PR newswire service

Tag Archives: contract research organization

Divergent CRO Announces Launch of New Contract Research Organization

Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplant